drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cell)
drug_description
FDA-approved autologous anti-CD19 CAR T-cell therapy with 4-1BB costimulation; patient T cells are engineered to express a CAR recognizing CD19, leading to T-cell activation, cytotoxicity, cytokine release, clearance of malignant B cells, and B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
tisagenlecleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an anti‑CD19 chimeric antigen receptor with 4‑1BB costimulation, enabling recognition of CD19 on B-lineage cells and triggering T‑cell activation, proliferation, cytokine release, and cytotoxic killing of malignant B cells, resulting in clearance of CD19+ disease and B‑cell aplasia.
drug_name
Tisagenlecleucel (KYMRIAH)
nct_id_drug_ref
NCT06408194